OP0111 A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL EXAMINING METHOTREXATE AND ETANERCEPT AS MONOTHERAPY OR IN COMBINATION FOR TREATING PSORIATIC ARTHRITIS: A COMPARISON OF THE COMPOSITE MEASURES USED TO EVALUATE DISEASE ACTIVITY. (June 2019)

• Record Type: Journal Article
• Authors: Mease, Philip J; Gladman, Dafna D; Collier, David; Ritchlin, Christopher T.; Helliwell, Philip; Coates, Laura C; Strand, Vibeke; Liu, Lyrica; Kricorian, Greg; Chung, James
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 129
• Page End: 129
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.783
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Optimal treatment regimens and measuring outcomes in psoriatic arthritis (PsA) remain key areas of research. Objectives: To examine methotrexate (MTX) and etanercept (ETN) as monotherapy or in combination in a randomized trial and assess the relative performance of PsA-specific composite measures using trial efficacy data. Methods: Patients with active PsA naïve to biologic drugs (no prior MTX for PsA) were randomized to 3 groups for 48 weeks: ETN 50mg+MTX 20mg weekly (Combo; N=283); ETN 50mg+placebo weekly (ETN-mono; N=284); or MTX 20mg+placebo weekly (MTX-mono; N=284). At week 24, the American College of Rheumatology (ACR)20 and Minimal Disease Activity (MDA) responses were the primary and key secondary endpoints, respectively. Other PsA-specific composite measures used for disease activity included the Psoriatic Arthritis Disease Activity Score (PASDAS) and Disease Activity Index for Psoriatic Arthritis (DAPSA). Results: Baseline characteristics were well balanced in the 3 arms. Mean (SD) age was 48.4 (13.1) years and mean/median PsA duration 3.2/0.6 years. ACR20 and MDA responses at week 24 were significantly greater with ETN-mono vs MTX-mono and Combo vs MTX-mono; ETN-mono and Combo had similar results (Table). PASDAS also showed differences between each ETN-containing arm vs MTX-mono and no difference for ETN-mono vs Combo, whereas study arm differences were not seen with DAPSA. PASDAS had a greater effect size and standardized response than DAPSA. Conclusion: In this large randomized, controlled PsA trial, ETN-mono or Combo had greater efficacy than MTX-mono. Combining ETN and MTX did not improve ETN efficacy. Compared with the joint-focused DAPSA, PASDAS captured a wider range of PsA manifestations and performed better in this trial. Disclosure of Interests: : Philip J Mease Grant/research support from: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Consultant for: AbbVie, Amgen, BMS, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer, SUN and UCB, Speakers bureau: AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer and UCB, Dafna D Gladman Grant/research support from: AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, David Collier Shareholder of: Amgen Inc., Employee of: Amgen Inc., Christopher T. Ritchlin Grant/research support from: AbbVie, Amgen, UCB Pharma, Consultant for: AbbVie, Amgen, Lilly, Novartis, Pfizer, UCB Pharma, Philip Helliwell Grant/research support from: Paid to charity: from AbbVie, Janssen and Novartis, Consultant for: Paid to charity: from AbbVie, Amgen, Pfizer, and UCB and Celgene. Paid to self: from Celgene and Galapagos, Laura C Coates Grant/research support from: AbbVie, Celgene, Lilly, Novartis and Pfizer, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead Sciences Inc., Janssen, Lilly, Novartis, Pfizer, Prothena Corp and UCB, Vibeke Strand Consultant for: AbbVie, Amgen, Bayer, BMS, Boehringer Ingelheim, Celgene, Celltrion, CORRONA, Crescendo, EMD Serono, Genentech/Roche, GSK, Horizon, Inmedix, Janssen, Kezar, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, Servier, UCB., Lyrica Liu Shareholder of: Amgen Inc., Employee of: Amgen Inc., Greg Kricorian Shareholder of: Amgen Inc., Employee of: Amgen Inc., James Chung Shareholder of: Amgen Inc., Employee of: Amgen Inc.